Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


24.05.24 / Tradegate WKN: A2PSR2 / Name: BioNTech / Stock / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

BioNTech SE ADR Stock

We can see a decrease in the price for BioNTech SE ADR. Compared to yesterday it has lost -€2.300 (-2.510%).
With 13 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 107 € shows a slightly positive potential of 19.75% compared to the current price of 89.35 € for BioNTech SE ADR.
For the coming years our community has positive and negative things to say abot the BioNTech SE ADR stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.

Pros and Cons of BioNTech SE ADR in the next few years

W********* I********* f** t** n*** y****
G***** c******* t* c**********
C******** o* t** e**********
M***** P*******
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17

Upon initial examination, the financial statements of BioNTech, a company operating within the pharmaceutical industry, present a strong financial position. The company has exhibited consistent growth, maintaining robust liquidity, and profitability ratios.

Asset Growth: BioNTech's total assets increased significantly from €2.31 billion in 2020 to €23.28 billion in 2022, showcasing robust growth within just two years. Particularly, current assets, such as cash and receivables, have exhibited remarkable expansion.

Profitability: The company displays impressive net income figures, from €15.2 million in 2020 to a staggering €9.43 billion in 2022. This increase in net income underscores the company's ability to generate substantial profits.


Prediction Buy
Perf. (%) 3.38%
Target price 170.000
Ends at 17.12.22

Target price set to 170.0
Show more

Buy BioNTech SE ADR
Show more

Buy BioNTech SE ADR
Show more